ROLE OF INTESTINAL MICROFLORA IN THE DEVELOPEMENT OF IRRITABLE BOWEL SYNDROME (IBS) AND IBS-LIKE VIOLATIONS. TREATMENT ISSUES


Cite item

Full Text

Abstract

The article presents the modern view on the pathogenesis of irritable bowel syndrome (IBS) and IBS-like violations in various diseases of the gastrointestinal tract; detailed criteria for diagnosis of major variants of IBS and IBS-like disorders, as well as the postinfection IBS are represented. The role of intestinal motility disorders and microflora in the development of the major clinical manifestations of IBS is clarified. The steps of myocyte contraction and mechanisms of action of antispasmodics are described in detail. Modern tactics of medical management of patients with IBS, which is aimed to normalization of motor disorders with the use of antispasmodics, particularly selective myotropic spasmolytic pinaverium bromide (Dicetel), as well as the restoration of intestinal microbiocenosis are presented.

References

  1. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-31.
  2. Farrokhyar F, Marshall JK, Easterbrook B, et al. Functional Gastrointestinal Disorders and Mood Disorders in Patients with Inactive Inflammatory Bowel Disease: Prevalence and Impact on Health. Inflam Bowel Dis 2006;12(1):38-45.
  3. Drossman DA. The Functional Gastrointestinal Disorders and the Rome III Process. Gastroenterology 2006;130(5).
  4. Григорьев П.Я., Яковенко Э.П. Синдром раздраженного кишечника, ассоциированный с дисбактериозом // Consilium medicum. 2003. Т. 2, № 7. С. 305-7.
  5. Yakovenko E, Grigoriev P. Tcherenchimediins at all. Is irritable bowel syndrome (IBS) related to altered gut flora? Gut 1997;41(Suppl. 3):123.
  6. Dunlop SP, Jenkins D, Spiller RS. Distinctive clinical, psychological and histological features of postinfective irritable bowel syndrome. American J Gastroenterology 2003;98(7):1578-83.
  7. Tazume S, Ozawa A, Yamamoto T, et al. Ecological study on the intestinal bacteria flora of patients with diarrhea. Clin Infect Dis 1993; 6 (Suppl. 2):77-82.
  8. Stewart GT. Post-dysenteric colitis. BMJ 1950;1:405-9.
  9. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: post al survey of patients. BMJ 1997;314:779-82.
  10. Tornblom H, Holmvall P, Svenungsson B, Lindberg G. Gastrointestinal symptoms after infections diarrhea: a five-year follow up in a swedish cohort of adults. Clin Gastroenterol Hepatol 2007;5:461-64.
  11. Парфенов А.И., Ручкина И.Н., Атуллаханов Р.И. и др. Постинфекционный синдром раздраженной кишки // Тер. арх. 2009. Т. 81, № 2. С. 39-45.
  12. Gwee KA, Collins SM, Read NW, et al. Increased rectal mucosal expression of interleukin 1 beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003;52:523-6.
  13. Маев И.В., Черемушкин С.В. Психосоциальные факторы в развитии синдрома раздраженной кишечника, возможности терапии // Consilium medicum. 2006. № 7. С. 34-42.
  14. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfections IBS. Gastroenterology 2003;125:1651-59.
  15. Парфенов А.И., Ручкина И.Н., Осипов Г.А. Висмута трикалия дицитрат в лечении больных постинфекционным синдромом раздраженного кишечника // РМЖ 2006. Т. 8, № 2. С. 78-81.
  16. Drossman DA. Treatment for bacterial overgrowth in the irritable bowel syndrome. Ann Intern Med 2006;145:626-628.
  17. Яковенко Э.П., Агафонова Н.А., Яковенко А.В. и др. Роль моторных нарушений в механизмах формирования клинических проявлений синдрома раздраженной кишки (СРК) и СРК-подобных нарушений. Вопросы терапии // Consilium Medicum. 2011. № 1. С. 69-73.
  18. Morel N, Buryi V, Feron O, et al. The action of calcium channel blockers on recombinant L-type calcium channel α1-subunits. Br J Pharmacol 1998;125:1005-12.
  19. Christen MO. Pinaverium bromide: A calcium antagonist with selectivity for the gastrointestinal tract. Today's Therapeutic Trends 1995;13(2):47-62.
  20. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15:355-36.
  21. Яковенко Э.П., Иванов А.Н., Агафонова Н.А. и др. Нарушение нормального состава кишечных бактерий: клиническое значение и вопросы терапии // РМЖ 2008. Т. 10, № 2. С. 41-6.
  22. Всемирная Гастроэнтерологическая ассоциация. Практические рекомендации. Пробиотики и пребиотики. Май, 2008, Availablefrom.
  23. Martin H, et al. Recommendations for Probiotic Use. Clin Gastroenterol 2008;42(Suppl. 2):104-8.
  24. Lancaster-Smith MJ, Prout BJ, Pinto T, et al. Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity. Acta Psychiatr Scand 1982;66:33-41.
  25. Gorard DA, Libby GW, Farthing MJG. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci 1995;40:86-95.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies